tiprankstipranks
Advertisement
Advertisement
Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target
PremiumThe FlyBiohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target
1M ago
Controversial Prasad leaving FDA, NYT reports
Premium
The Fly
Controversial Prasad leaving FDA, NYT reports
1M ago
Biohaven price target lowered to $10 from $11 at H.C. Wainwright
Premium
The Fly
Biohaven price target lowered to $10 from $11 at H.C. Wainwright
1M ago
Midday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan’s
PremiumThe FlyMidday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan’s
3M ago
Biohaven upgraded to Outperform from Sector Perform at RBC Capital
Premium
The Fly
Biohaven upgraded to Outperform from Sector Perform at RBC Capital
3M ago
Biohaven price target raised to $15 from $10 at BofA
Premium
The Fly
Biohaven price target raised to $15 from $10 at BofA
3M ago
Biohaven: Core Pipeline Strength and Upcoming Clinical Catalysts Support Buy/High Risk Rating Despite BHV-7000 MDD Setback
PremiumRatingsBiohaven: Core Pipeline Strength and Upcoming Clinical Catalysts Support Buy/High Risk Rating Despite BHV-7000 MDD Setback
3M ago
Biohaven reports BHV-7000 trial misses primary endpoint
Premium
The Fly
Biohaven reports BHV-7000 trial misses primary endpoint
4M ago
Biohaven presents data for BHV-1510 at ESMO
Premium
The Fly
Biohaven presents data for BHV-1510 at ESMO
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100